Dren Bio, Inc.

Sanofi’s immunology pipeline has suffered a couple of high-profile setbacks recently so the proposed acquisition of Blueprint Medicines Corp and Ayvakit, its already-approved therapy for advanced sy

Metabolic disease alliances have picked up as companies try to find a spot in the growing obesity market, and earlier this decade the COVID-19 pandemic drove a short-lived uptick in infectious disea

Sanofi has taken another step on the path to becoming the world’s leading immunology company by paying $600m to acquire Dren Bio’s DR-0201, an early-stage bispecific myeloid cell engager. The French f

In Vivo’s editors, along with experts from the wider Citeline team, have selected our top four picks for the most significant M&A, alliance and financing deals of 2024. Vote now in the polls belo